US FDA approves Algeta’s Xofigo injection for castration-resistant prostate cancer
Xofigo is the first alpha particle-emitting radioactive therapeutic agent that has showed improvement in overall survival (OS) and delay in time to first symptomatic skeletal event (SSE) compared